Skip to main content

Dr. Gabriel N. Mannis, MD

Medical Oncology (Medical Oncology Physician)

300 Pasteur Dr
Stanford, CA 94305

Who else practices at this address →

Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas

Call (650) 723-4000

  • Medicare participating

At a glance

Years since graduation
18
In the NPI registry since
2009
Medicare patients seen, 2024
132

Licensed in California since 2010, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2008Medical school: University of California, Davis School of Medicine
  • 2009Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    CA license A110736 (first issued 2010; current)
  • Hematology (Internal Medicine) Physician
    CA license A110736 (first issued 2010; current)
  • Hematology & Oncology Physician
    CA license A110736 (first issued 2010; current)
  • Internal Medicine Physician
    CA license A110736 (first issued 2010; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
132
Services billed
696
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes29257
Established patient office or other outpatient visit, 40-54 minutes23162
Established patient office or other outpatient visit, 30-39 minutes18669
Hospital discharge day management, more than 30 minutes3830
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes3733
New patient office or other outpatient visit, 60-74 minutes2323

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Venclexta (venetoclax)57
Inqovi (decitabine/cedazuridine)18
Tibsovo (ivosidenib)18
Allopurinol
Other prescribers in Stanford, CA
11
Cresemba (isavuconazonium sulfate)11
Vanflyta (quizartinib dihydrochloride)11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 27 payments worth $29,416 in total to this clinician.

By company
AbbVie Inc.$9,290
Taiho Oncology, Inc.$3,900
Astellas Pharma Global Development$3,718
Daiichi Sankyo Inc.$3,393
Janssen Scientific Affairs, LLC$2,659
Stemline Therapeutics Inc.$2,340
Genentech USA, Inc.$1,847
Syndax Pharmaceuticals, Inc.$800
By type
Consulting Fee$27,877
Food and Beverage$854
Honoraria$685

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 19, 2025Taiho Oncology, Inc.
Feb 19, 2025
Consulting Fee
INQOVI · Oncology
$3,900
Dec 23, 2025Daiichi Sankyo Inc.
Dec 23, 2025
Consulting Fee
Vanflyta · ONCOLOGY
$3,225
Apr 30, 2025Astellas Pharma Global Development
Apr 30, 2025
Consulting Fee
Xospata · Oncology
$2,704
Sep 23, 2025Janssen Scientific Affairs, LLC
Sep 23, 2025
Consulting Fee$2,503
Apr 18, 2025Stemline Therapeutics Inc.
Apr 18, 2025
Consulting Fee
ELZONRIS · Oncology
$2,340
Jan 2, 2025AbbVie Inc.
Jan 2, 2025
Consulting Fee$2,100
Dec 19, 2025AbbVie Inc.
Dec 19, 2025
Consulting Fee$2,100
Feb 20, 2025AbbVie Inc.
Feb 20, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$1,750
Jan 17, 2025AbbVie Inc.
Jan 17, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$1,725
Dec 6, 2025Genentech USA, Inc.
Dec 6, 2025
Consulting Fee
Venclexta · BioOncology
$1,640
All 16 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 23, 2025Daiichi Sankyo Inc.
Dec 23, 2025
Consulting Fee
Vanflyta · ONCOLOGY
$3,225
Dec 22, 2025Syndax Pharmaceuticals, Inc.
Dec 22, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$800
Dec 19, 2025AbbVie Inc.
Dec 19, 2025
Consulting Fee$2,100
Dec 6, 2025Genentech USA, Inc.
Dec 6, 2025
Consulting Fee
Venclexta · BioOncology
$1,640
Oct 17, 2025Astellas Pharma US Inc
Oct 17, 2025
Consulting Fee
Xospata · Oncology
$676
Sep 23, 2025Janssen Scientific Affairs, LLC
Sep 23, 2025
Consulting Fee$2,503
Sep 5, 2025Rigel Pharmaceuticals, Inc.
Sep 5, 2025
Honoraria
Rezlidhia · Acute Myeloid Leukemia
$685
May 28, 2025AbbVie Inc.
May 28, 2025
Consulting Fee$700
Apr 30, 2025Astellas Pharma Global Development
Apr 30, 2025
Consulting Fee
Xospata · Oncology
$2,704
Apr 18, 2025Stemline Therapeutics Inc.
Apr 18, 2025
Consulting Fee
ELZONRIS · Oncology
$2,340
Mar 21, 2025Astellas Pharma Global Development
Mar 21, 2025
Consulting Fee
Xospata · Oncology
$1,014
Mar 6, 2025AbbVie Inc.
Mar 6, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$700
Feb 20, 2025AbbVie Inc.
Feb 20, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$1,750
Feb 19, 2025Taiho Oncology, Inc.
Feb 19, 2025
Consulting Fee
INQOVI · Oncology
$3,900
Jan 17, 2025AbbVie Inc.
Jan 17, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$1,725
Jan 2, 2025AbbVie Inc.
Jan 2, 2025
Consulting Fee$2,100

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $637,398 in research payments for these studies, mostly to the institutions running them.

  • ASTX727-07
    Taiho Oncology, Inc.
  • A phase 1/2, open-label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemias, including those harboring an mll/KMT2A gene rearrangement or nucleophosmin 1 (NPM1)…
    Syndax Pharmaceuticals, Inc.
  • Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
    Daiichi Sankyo Inc. · Active, not recruiting · NCT06578247
  • STML-401-0423 - a phase ii multicenter open -label trial of tagraxofusp (tag) in combination with venetoclax and azacitidine (ven/aza) in adults with previously untreated CD123+ acute myeloid leukemia (aml) who are i…
    Stemline Therapeutics Inc.
  • Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemi…
    Taiho Oncology, Inc.
  • Study name not reported
    Siemens Medical Solutions USA, Inc.
  • Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
    Taiho Oncology, Inc.
  • A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
    Sumitomo Pharma America, Inc. · Recruiting · NCT04988555

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Stanford

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 12, 2024), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1881929347. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.